PERRIGO Co plc 8K

Perrigo has appointed Albert Manzone as Interim President and CEO under a fixed‑term contract with specified compensation, equity, and termination terms.

Perrigo Pharma International D.A.C., an affiliate of Perrigo Company plc, has entered into a fixed‑term employment agreement with Albert Manzone appointing him as Interim President and Chief Executive Officer effective June 7, 2026 through December 31, 2026, with a potential month‑to‑month extension of up to 90 days, setting his annual base salary at $1,270,000, detailing termination, notice, indemnification, and confidentiality provisions, and providing for a one‑time $2.5 million RSU grant under the Perrigo Company plc 2026 Long‑Term Incentive Plan, a $250,000 completion bonus subject to performance metrics, and various allowances and tax support.

Filing Facts

CIK

1585364

Ticker

PRGO

Form

8K

Source Type

sec

Accession

0001585364-26-000110

Alert Tier

7